We describe a new murine monoclonal antibody, OP-G2, against platelet glycoprotein (GP) IIb/IIIa that induces platelet aggregation and release of ATP from platelets. OP-G2 was an IgGI antibody, which did not react with platelets from two patients with Glanzmann's thrombasthenia and immunoprecipitated GP IIb and GP IIIa from solubilized radiolabeled normal platelets. In the concentration range of 2'80 pg/ml of IgG, OP-G2 induced platelet aggregation with a lag phase in PRP from 11 of 20 normal subjects. The lag phase decreased with the increasing concentration of OP-G2 in 9 of 11 normal subjects. It is noteworthy, however, that the intensity of maximal aggregation paradoxically decreased at higher concentration than 32 pg/ml. In contrast to intact OP-G2 IgG, no aggregation was observed by Fab of OP-G2. The increasing amounts of OP-G2 (Fab) prolonged the lag phase of platelet aggregation induced by OP-G2 (IgG, 20 pg/ml). Finaly, OP-G2 (Fab, 40 pg/ml) completely inhibited OP-G2-induced platelet aggregation including the shape change. These data indicated that the platelet aggregation was mediated by Fab region of OP-G2. Furthermore, OP-G2 (Fab) inhibited dose-dependently ADP-, epinephrine-, and
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